US Patent

US12037644 — Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2035-10-18 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for identifying cancer patients who will respond to treatment with an FGFR inhibitor, such as Balversa, by testing for specific FGFR gene mutations.

USPTO Abstract

Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (FGFR) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more FGFR mutants from a FGFR mutant gene panel. Kits and primers for identifying the presence of one or more FGFR mutant genes in a biological sample are also disclosed herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3972 — Balversa
U-3972 — Balversa
U-3972 — Balversa

Patent Metadata

Patent number
US12037644
Jurisdiction
US
Classification
Method of Use
Expires
2035-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.